Alexander's, Inc.

Fundamentals4.0
Price Action4.0
News Sentiment5.0
AI Rating
4.0

Key Drivers

  • Earnings Surge
  • High Leverage
  • Dividend Risk

AI
AI Summary

4.0

ALX is a high-yield, asset-backed REIT—not a 7.9x earnings bargain—because its recent profit was largely driven by a one-time property sale; investors should demand proof that recurring rental cash flow can cover the ~7% dividend while leverage remains high, with the Target lease and stronger cash balance offering only partial support.

DividendIncome‍
CoverageRisk
TargetLease

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • •Earnings Surge
  • •High Leverage
  • •Dividend Risk

ALX's improved Q2 earnings, liquidity, and apparent valuation are tempered by high leverage, inconsistent cash flow, and an unsustainably high annual dividend payout.

CautiousOutlook
ValueWatch

Price Behavior

4.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • •Accelerating decline
  • •Oversold momentum
  • •Critical support

ALX fell 9.2% over the last month, remains weak below $260.90, and may bounce from $245–$247 support, but a break below $245 would reinforce the downtrend.

OversoldBounce
BearishTrend
Support Level: $245–$247
Resistance Level: $250–$253, then $261–$265

Accelerated selloff to $245.65 between 2026-09-08 and 2026-09-15

Sentiment & News

5.0

Key News Insights:

  • •Peer comparisons
  • •Investor conferences
  • •No financial updates

Alexander's saw comparative stock analyses without a stated verdict, while ALX Oncology focused on September investor-conference outreach, signaling neutral near-term catalysts.

ALX
ALXO

The coverage is unlikely to materially affect either instrument without new operating results, guidance, or transactions